Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor

Haematologica. 2020 Oct 1;105(10):e497. doi: 10.3324/haematol.2019.236182.

Authors

Naoya Uchida¹, Alexis Leonard¹, David Stroncek², Sandhya R Panch², Kamille West², Eoghan Molloy², Thomas E Hughes³, Sara Hauffe⁴, Tiffani Taylor¹, Courtney Fitzhugh¹, Jane S Hankins⁵, Megan Wilson⁵, Akshay Sharma⁶, Shengdar Q Tsai⁵, Mitch J Weiss⁵, Matthew Hsieh¹, John F Tisdale¹

Affiliations

¹ NHLBI, NIDDK, National Institutes of Health (NIH), Bethesda, USA.
² Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA.
³ Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD.
⁴ Hematology Branch, NHLBI, NIH, Bethesda, USA.
⁵ Department of Hematology, St. Jude Children Research Hospital (SJCRH), Memphis, USA.
⁶ Department of Bone Marrow Transplantation and Cellular Therapy, SJCRH, Memphis, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Sickle Cell* / therapy
Antigens, CD34
Benzylamines
Cyclams
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Heterocyclic Compounds*
Humans
Multiple Myeloma* / therapy
Peripheral Blood Stem Cell Transplantation*
Peripheral Blood Stem Cells*
Transplantation, Autologous

Substances

Antigens, CD34
Benzylamines
Cyclams
Heterocyclic Compounds
Granulocyte Colony-Stimulating Factor
plerixafor

Grants and funding